Business Wire

BioAuxilium Research Launches New THUNDER™ TR-FRET Biomarker Assay Kits and an Enhanced Assay Development Service for Drug Discovery


At the annual Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in San Diego,BioAuxilium Research Inc., a biotech tool company focused on facilitating access to fully validated assay kits to the biomedical research community, today announced the expansion of its no-wash THUNDER™ time-resolved Förster resonance energy transfer (TR-FRET) technology portfolio by introducing six new biomarker research assay kits, a Reader Control Kit, and an enhanced assay development service for drug discovery research.

BioAuxilium developed the new biomarker assays in response to customer requests for reliable cell-based assays that provide an alternative to expensive immunoassay platforms such as other TR‑FRET and bead-based assay technologies. The new offerings include a panel of six key mouse inflammatory cytokines (CCL-2/MCP1, IFN-beta, IFN-gamma, IL-2, IL-6, and TNF-alpha), expanding the company’s portfolio to a total of 100 cell-based assay kits (76 Cell Signaling Kinases, 23 Biomarkers, and a cAMP Assay). The ready-to-use Reader Control Kit allows users to assess in just 10 minutes the suitability of TR‑FRET compatible microplate readers to perform Europium-based TR-FRET measurements.

The new assay development service offers three types of custom assay solutions: labeling of antibodies with BioAuxilium’s proprietary TR-FRET fluorophores, custom assay development services, and custom kit development services. These comprehensive, yet flexible custom solutions are designed to fast-track assay development, while further reducing risk, turnaround time, and cost.

“BioAuxilium continues to make great strides with the expansion of the THUNDER™ TR-FRET technology portfolio, based on customer demand for high-performing, reliable yet affordable immunoassays,” said Jaime Padros, PhD, President, BioAuxilium Research. “In addition, our decades of experience developing and manufacturing drug discovery assays based on TR-FRET allow us to deliver results within turnaround times and at prices simply unattainable by any other custom assay development service.”

BioAuxilium’s THUNDER™ TR-FRET technology is a robust, proprietary platform based on a FRET pair showing an enhanced spectral compatibility and TR-FRET signal, best antibody pairs selected specifically for TR-FRET, and a panel of optimized lysis and assay buffers. In addition, the “add-incubate-read” protocol of the immunoassay platform, combined with its full compatibility with different TR-FRET readers, facilitates streamlined workflows and automation for high-throughput screening. All THUNDER™ TR-FRET assays are extensively validated to ensure specificity, sensitivity, reproducibility, and lot-to-lot consistency.

About BioAuxilium Research Inc.

BioAuxilium is a private Canadian biotechnology tool company founded by expert assay scientists. It focuses on developing and manufacturing top-quality, highly validated assay kits that accelerate drug discovery and basic research. BioAuxilium’s kits are based on its enhanced proprietary THUNDER™ TR‑FRET technology. They are offered at an outstanding value and are accompanied by information-rich datasheets and expert technical support. BioAuxilium also provides customized services in assay development on a contract basis. Their products and services are available directly to US- and Canada-based customers, and through the company’s network of international distributors.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Jaime Padros, President
514-312-9033 ext. 101

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Norges Bank Terminates Its Observation On Kirin Holdings23.3.2023 06:00:00 CET | Press release

Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) today announces that Norges Bank has terminated its observation on Kirin Holdings on March 22 2023, recognizing the completion of the Myanmar business transfer. 1. Background Based on a recommendation of Norway’s Council on Ethics*1, Norges Bank placed Kirin Holdings under observation with the possibility of exclusion from its Government Pension Fund Global in March 2021*2. Following Kirin Holdings’ decision on the withdrawal from the Myanmar business in February 2022 and the basic agreement on the share transfer of the local joint venture Myanmar Brewery Limited in June 2022, Kirin Holdings announced the completion of the share transfer on January 23, 2023*3. Again, based on the recommendation of the Council on Ethics*4, Norges Bank terminated its observation on Kirin Holdings on March 22 2023*5. In addition, the following measures have been agreed upon to take to ensure the treatment of local employees. (1) Ensure freedom o

Hyundai Motor Company and Advent Technologies Sign Joint Development Agreement Following Successful Fuel Cell Technology Assessment23.3.2023 01:25:00 CET | Press release

Hyundai Motor Company today announced a successful technology assessment with Advent Technologies Holdings, Inc. (“Advent”), an innovation-driven leader in the fuel cell and hydrogen technology sectors. The assessment evaluated Advent's proprietary Membrane Electrode Assembly (“MEA”) technology for supplying Hyundai’s high-temperature fuel cell needs, and following its success, the two companies have entered into a Joint Development Agreement (“JDA”). This press release features multimedia. View the full release here: From left to right: Seung Hyun Hong, Ph.D. (Vice President, Materials Research & Engineering Center, Hyundai), Jim Coffey (Chief Operating Officer & General Counsel, Advent Technologies) (Photo: Business Wire) The signing ceremony took place on March 22, 2023, at Advent’s headquarters in Charlestown, Massachusetts, and included senior executives from both companies. Under the agreement, Hyundai and Advent will work

Bentley Systems Announces Strategic Agreement with Worldsensing22.3.2023 21:01:00 CET | Press release

Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced it has entered into a non-exclusive commercial agreement to strategically accelerate the adoption of Infrastructure IoT, further unlocking value for infrastructure designers, constructors, and owner-operators in their use of infrastructure digital twins. To this end, Worldsensing is acquiring from Bentley sensemetrics’ Thread connectivity device business to expand its hardware portfolio offerings. Bentley also becomes the lead investor in Worldsensing’s Series D capital raise. This press release features multimedia. View the full release here: Worldsensing’s Connectivity Devices fully integrated with Bentley’s sensemetrics software and iTwin IoT cloud services. Image courtesy of Worldsensing. Worldsensing’s acquisition of the Thread connectivity device business will offer new options to its customers where adaptive senso

Incyte Announces FDA Approval of Zynyz ™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)22.3.2023 18:14:00 CET | Press release

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz™ (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). The Biologics License Application (BLA) for Zynyz for this indication has been approved under accelerated approval by the U.S. FDA based on tumor response rate and duration of response (DOR). Continued approval of Zynyz for this indication may be contingent on verification and description of clinical benefit in confirmatory trials. MCC is a rare and aggressive type of skin cancer that frequently appears as a single, painless, reddish-purple skin nodule on the head, neck and arms in skin exposed to sunlight1. MCC tends to grow quickly and has a high rate of metastatic disease, leading to a poor prognosis2,3. The estimated five-year overall survival (OS) rate is 14% in patients with MC

Mary Kay Highlights the Importance of Women’s Leadership and Private Sector Engagement in Conservation at the World Ocean Summit 2023 Hosted by Economist Impact22.3.2023 17:02:00 CET | Press release

Mary Kay Inc., a global advocate for corporate sustainability and signatory to the UN Global Compact Sustainable Ocean Principles, continues to play an important role in ocean conservation. In February, the beauty brand launched a groundbreaking, user-friendly platform offering valuable guidance, decision-support tools, and practical knowledge for marine practitioners. Following the announcement, Mary Kay recently participated at the 10th World Ocean Summit and Expo 2023 in Lisbon, Portugal, organized by Economist Impact. This press release features multimedia. View the full release here: Sandra Silva, Mary Kay Portugal’s General Manager participates on a panel on the topic of "Putting Coral Reef Restoration at the Heart of Ocean Conservation Action" at the World Ocean Summit in Lisbon, Portugal (Credit: Mary Kay Inc.). The World Ocean Summit is an annual global event that brings together the widest cross-section of the ocean co